Artificial intelligence is rapidly changing how healthcare professionals diagnose disease. But can computers identify kidney damage before it becomes obvious under a microscope? Researchers believe the answer may be yes. The combination of digital pathology, artificial intelligence, and diabetic kidney disease research is opening new opportunities to identify microscopic kidney …
Read More »Could We Predict Diabetic Neuropathy Years Before Symptoms Begin?
Early detection has always been one of the biggest challenges in diabetes care. What if doctors could identify patients at high risk for diabetic neuropathy or kidney disease years before symptoms developed? That possibility is driving exciting new research into IgG glycosylation in diabetes, an emerging area that examines subtle …
Read More »A Newly Discovered Form of Cell Death May Explain Why Diabetes Causes So Many Complications
Diabetes is known for raising blood sugar levels, but its long-term complications often have the greatest impact on health. Kidney disease, vision loss, nerve damage, and cardiovascular disease affect millions of people living with diabetes. For years, researchers focused on inflammation, oxidative stress, and poor circulation to explain these complications. …
Read More »Not All Diabetic Kidney Disease Is the Same—Scientists Just Found a Hidden Subtype
For years, diabetic kidney disease (DKD) has been viewed as a single condition that progresses in a fairly predictable way. However, new research suggests that this assumption may overlook important biological differences between patients. Scientists have now identified a previously hidden subtype of diabetic kidney disease marked by increased B-cell …
Read More »Farxiga Just Went Generic—Will Lower Prices Finally Change Diabetes Care?
For many people living with type 2 diabetes, the biggest challenge is not finding an effective medication. It is being able to afford it. That reality may begin to change now that the U.S. Food and Drug Administration (FDA) has approved the first generic versions of Farxiga (dapagliflozin), potentially making …
Read More »Beyond SGLT2 Inhibitors: Why Non-Steroidal MRAs Are Becoming the Third Pillar of Kidney Protection
For years, the treatment of diabetic kidney disease focused primarily on glycemic control and blood pressure management. More recently, SGLT2 inhibitors and GLP-1 receptor agonists have transformed the landscape by reducing kidney disease progression and cardiovascular events. However, another therapeutic class is rapidly gaining recognition. Non-steroidal mineralocorticoid receptor antagonists (MRAs) …
Read More »Implementing CKM Staging in Primary Care: From Concept to Workflow
The concept of CKM staging in primary care has gained attention as clinicians look for better ways to manage the growing overlap between cardiovascular disease, kidney disease, diabetes, and metabolic disorders. However, many providers still wonder how to translate the CKM framework into daily clinical practice. Think of CKM staging …
Read More »GLP-1s and CKD Progression: Are Anti-Inflammatory Effects Clinically Meaningful?
Chronic kidney disease (CKD) remains one of the most serious complications associated with diabetes, affecting millions of patients worldwide. While SGLT2 inhibitors have become foundational therapies for protecting kidney function, researchers are increasingly examining whether other drug classes may also slow renal decline. In particular, growing interest surrounds how GLP-1 …
Read More »Social Determinants First: Using CKM and SDOH to Sequence Diabetes Therapies in 2026
A patient’s A1C can look acceptable on paper while everything else is quietly heading in the wrong direction. Cardiovascular risk is rising, kidney function is slipping, and the patient keeps missing follow-up visits because of cost, transportation, or work constraints. Most clinicians have seen this scenario play out, even when …
Read More »CKM in the Wild: Applying the 2026 ADA Cardiometabolic Framework to a Real Panel
What happens when a guideline finally reflects the complex realities of patient care? The ADA’s 2026 CKM standards aim to do just that—merging heart, kidney, and metabolic health into one actionable framework. But translating those recommendations into daily clinical decision-making isn’t always straightforward. This article walks through real-world composite cases …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.